Market Newsdesk

TORONTO, Dec. 16, 2020 (GLOBE NEWSWIRE) — ARHT Media Inc. (“ARHT” or “the Company”) (TSXV:ART), the global leader in the development, production and distribution of high-quality, low latency hologram and digital content, is pleased to announce that they have entered into a reseller agreement with Electronics & Engineering Pte Ltd (E&E), a leading AV integrator & distributor based in Singapore.

With over 70 years of experience and a presence across Singapore, Malaysia and Indonesia, E&E has completed projects of various sizes in many industries within Singapore and the region. As part of the agreement, E&E will open a permanent demo studio that will feature ARHT’s HoloPresence^TM Display technology as well as provide a permanent location where a speaker can be captured for client activations.

“This strategic partnership with ARHT Media will allow us to provide our Clients with a powerful connection to their audiences using ARHT’s HoloPresence™ Display technology. We are to launch a permanent Capture studio in the coming months which will enable speakers to have simultaneous presentations and reach their audiences seamlessly while eliminating the challenges of time and distance no matter where they may be.” commented Gary Goh, Deputy Managing Director at E&E.

“E&E is the perfect reseller and technical support partner for ARHT in Singapore. The depth of their relationships and AV experience in permanent installations as well as in the events industry is such a great match for our technologies – that are revolutionizing both special events and everyday communication,” stated ARHT CEO Larry O’Reilly. “Singapore is important geographically and is a leader in technological innovation. Showcasing our technology with a partner that carries the highest standards will reflect very well for both of our brands

As ARHT Media’s technical and sales partner in the region E&E will sell our HoloPresence^TM and HoloPod™ in person communication technology and provide technical support and training for ARHT Media products and services. ARHT will support E&E’s activation and sales initiatives through the ARHT Partner Program, which provides resources for marketing, technical training, and business development support.

ARHT’s growing global partner network now includes relationships with integrators and resellers in Singapore, Korea, China, Israel, Switzerland, Brazil, USA and Canada.

About Electronics & Engineering Pte Ltd

Electronics & Engineering Pte Ltd is the region’s leading Systems Integrator, Consultant, Specialist Contractor as well as being a Distributor and Supplier of a vast range of reputable Audio-Visual equipment since it was established in 1951.

For more information, please visit www.enepl.com.sg

About ARHT Media

ARHT Media’s patented HoloPresence technology is a complete end-to-end solution that creates a sense of presence for audiences – as though the holographic presenter was actually live in the room. With no noticeable latency, ARHT Media makes two-way live communication with a 3D holographic presenter anywhere in the world possible. We can also playback pre-recorded content and 3D animations on our HoloPresence displays to deliver rich holographic experiences. Add to this our capability to stream the same content online on our premium Virtual Global Stage^TM.

Connect with ARHT Media

Twitter: http://www.twitter.com/ARHTmedia
Facebook: http://www.facebook.com/ARHTmediainc
LinkedIn: http://www.linkedin.com/company/arht-media-inc-

For more information, please visit www.arhtmedia.com or contact the investor relations group at [email protected].

ARHT Media trades under the symbol “ART” on the Toronto Venture Stock Exchange.

Press Contact


Salman Amin

ARHT Media
[email protected]

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, disclosure related to the Company’s sales funnel; the Company’s technology; the potential uses for the Company’s technology; the future planned events using the Company’s technology; the future success of the Company; the ability of the Company to monetize the ARHT Media technology; the development of the Company’s technology; and interest from parties in ARHT’s products. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic and competitive uncertainties; regulatory risks; risks inherent in technology operations; and other risks of the technology industry. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

WILMINGTON, Del., Dec. 16, 2020 (GLOBE NEWSWIRE) — InterDigital, Inc. (NASDAQ:IDCC), a mobile and video technology research and development company, today provided revenue guidance for fourth quarter 2020.

The company expects total fourth quarter 2020 revenue to be between $84 million and $88 million, which includes revenues from two small license agreements signed since the beginning of the quarter, and approximately $1 million to $2 million in non-recurring revenue. This revenue guidance does not include the potential impact of any new patent license, technology solutions or patent sale agreements that may be signed, or any arbitration or dispute resolutions that may occur, during the balance of fourth quarter 2020.

“The guidance underscores our strong performance in 2020, putting us on track for double-digit revenue growth despite a very challenging environment in all markets worldwide,” said Richard Brezski, Chief Financial Officer.

About InterDigital

^®

InterDigital develops mobile and video technologies that are at the core of devices, networks, and services worldwide. We solve many of the industry’s most critical and complex technical challenges, inventing solutions for more efficient broadband networks, better video delivery, and richer multimedia experiences years ahead of market deployment. InterDigital has licenses and strategic relationships with many of the world’s leading technology companies. Founded in 1972, InterDigital is listed on NASDAQ and is included in the S&P MidCap 400^® index.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include information regarding the company’s current expectations with respect to fourth quarter 2020 revenue. Words such as “expects,” “projects,” “forecasts,” “anticipates,” and variations of such words or similar expressions are intended to identify such forward-looking statements.

Forward-looking statements are subject to risks and uncertainties. Actual outcomes could differ materially from those expressed in or anticipated by such forward-looking statements due to a variety of factors, including, but not limited to: (i) the entry into additional patent license, patent sales or technology solutions agreements; (ii) the accuracy of market sales projections of the company’s licensees, changes in our estimates of fourth quarter 2020 sales by our per-unit licensees, delays in payments from our licensees and related matters; (iii) amounts of royalties payable following routine audits, if any, and the timely receipt of such amounts during fourth quarter 2020; (iv) the timing, expenses, and outcome of the company’s litigation and arbitration proceedings and the timely receipt of any related awards; (v) new developments in the company’s litigation or arbitration proceedings; (vi) changes in our interpretations of, and assumptions and calculations with respect to the impact on the company of, the Tax Reform Act, as well as further guidance that may be issued regarding the Tax Reform Act; and (vii) the potential effects that the ongoing COVID-19 pandemic could have on our financial position, results of operations and cash flows. We undertake no duty to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise except as may be required by applicable law, regulation or other competent legal authority.

InterDigital is a registered trademark of InterDigital, Inc.

For more information, visit: www.interdigital.com.

InterDigital Contact:

Tiziana Figliolia
Email:[email protected]
+1 (302) 300-1857

TORONTO, Dec. 16, 2020 (GLOBE NEWSWIRE) — As Canada administers its first COVID-19 vaccine shots, a new national survey reveals that vacations, family reunions and high-risk loved ones are weighing heavily on the collective consciousness of Canadians. The Good Riddance 2020 Survey by Licenced Insolvency Trustees, Bromwich+Smith, focused on 2020’s ruined resolutions and renewed hope as a new year is upon us.

When asked “what are the top three things you’ll do after a vaccine becomes available and life starts to normalize,” booking a vacation led the way, with more than half (53%) choosing it as their top priority. “Hosting or attending a family reunion” was next (46%), followed by “visiting my grandparents or a high risk loved one” (38%). At the bottom of the list were things such as “swapping sweats and getting dressed up” (16%), “restarting my dating career” (9%) and “going clubbing” (7%).

“2021 is a year of hope and changed perspectives,” said Shawn Stack, Vice-President of Insolvency Practice, Bromwich+Smith. “A new year brings with it the opportunity of a reset. People are focused on what matters in life and what brings more meaning. They are happy in their sweats, less interested in clubbing and dating, and focused more on reconnecting and making memories.”

Curses – foiled again: 2020’s top cancelled resolutions

Amazingly, almost half of Canadians (47%) didn’t enter 2020 with a resolution. However, of those who had one, here were the 2020 New Year’s resolutions that were abandoned thanks to COVID-19.

• Travelling more was the top derailed resolution in 2020. Half of Canadians abandoned their plans as borders and regions were locked down around the world.
• Exercising more was the next victim of the 2020 cancel culture (41%), and gyms felt the brunt of that, along with cooped up Canadians.
• Improve my finances (spend less, earn more, get out of debt) became difficult to follow through on (33%) as the economy was essentially shut down for people and millions of jobs were lost.
• Eating healthier took a toll (27% cancellation rate) as we embraced our national sourdough making craze.

A new hope: lessons learned and plans for 2021

Finally, the number of people making a resolution for 2021 is up from last year. Four-in-five Canadians (78%) plan to have a resolution, much higher than the 53 per cent who did so last year. When asked what the biggest lessons learned from 2020 were that you will apply to the new year, here were the top responses:

• Supporting small and local businesses led the way, with six-in-10 saying that was their number one choice.
• This was essentially tied with “appreciate the little things in life (such as nature, art and beauty)” which clocked in at 59 per cent.
• Living more frugally and spending less on non-essentials, came in next at 47 per cent.
• This was followed closely by “be kinder to myself and others” (41%).
• “Explore my own ‘backyard’” (travel provincially or within my own community) was next with 35 per cent.

“There is a sense of resilience and hope in how Canadians, amidst considerable setbacks, have embraced certain values such as the importance of small business, being kind and appreciating what they have,” said Stack. “It is critical that Canadians realize, especially during these extraordinary times, that a lot of people are struggling mentally, physically and financially and they shouldn’t let stigma prevent them from getting help. 2021 is the year of the reset, it’s okay to reach out to professionals for financial and debt advice to help you restructure in the new year.”

The full results of the Good Riddance 2020 Survey are available through the contacts below. 

About t
he

Good Riddance 2020 Survey

by Bromwich+Smith

From December 9 to December 10, 2020 an online survey was conducted among a representative sample of 1,510 Canadians who are members of the Angus Reid Forum. For comparison purposes, the sample plan would carry a margin of error of +/- 2.5 percentage points, 19 times out of 20. Discrepancies in or between totals are due to rounding. 

About Bromwich+Smith

Bromwich+Smith, our dedicated team of Licensed Insolvency Trustees and Debt Relief Specialists are committed to rebuilding our clients’ worth, while helping relieve the overwhelming financial and emotional burden they are experiencing. Beyond our clients’ financial wellbeing, Bromwich+Smith strives to restore the personal wellbeing and self-confidence of every client. Whether it’s through a consumer proposal, bankruptcy, counselling or budgeting, our clients trust us to work with them to find customized solutions to make them whole again. With offices in BC, Alberta, Saskatchewan and Ontario, Bromwich+Smith helps thousands of Canadians each year rebuild their worth.

Bromwich+Smith’s Debt Relief Specialists are available for an initial consultation by phone at 1-855-884-9243 or via www.bromwichandsmith.com.

For further information: To arrange an interview with Shawn Stack, Vice President at Browmich+Smith please contact:

Dana Sharman

MAVERICK Public Relations
[email protected]
1-705-878-6493

Kim Jackson

Public Relations Specialist
Bromwich+Smith
[email protected]
1-403-801-0242

MIAMI, Dec. 16, 2020 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients, today announced KetaDASH www.ketadash.com, an Intravenous (IV) based, home delivery platform for patients who have been prescribed Ketamine.

Ehave, Inc. has entered into an asset purchase agreement to acquire the tangible and intangible assets of a San Diego, CA based IV therapy service CureDash www.curedash.com. CureDash currently operates an IV delivery platform that will become the backbone of KetaDash. KetaDASH will provide the platform for medical practitioners to administer Ketamine intravenously to patients at home. Ketamine is currently used to help ease pain and allows sedatives to be effective at lower doses, lessening the amount of potentially addictive pain medication required after certain medical procedures. Ketamine is now being studied as a treatment for major depression, though it has not yet been approved by the FDA to treat depression.

The KetaDASH platform will include software, staffing, protocols, and equipment. Ehave has designed a smart and intuitive dashboard for KetaDash from where the clients and the associated nurses can get detailed insight on how the Ketamine therapy is working. Patients will be able to create a profile, check availability of administering nurses, and schedule appointments.

According to Multidisciplinary Association for Psychedelic Studies, a non-profit research and educational organization, “There has been a recent explosion of interest in ketamine, a synthetic chemical with powerful antidepressant and visionary properties.” Ketamine was originally developed in the 1960s as a short-acting surgical anesthetic, however, it is emerging as a therapy for treatment-resistant depression, and showing benefits in the treatment of both unipolar and bipolar depression. A recent article on RealMoney.com said, “While there is a lot of fuss about a potential legal market for psilocybin, ketamine is currently where the money is for alternative plant medicine companies. Ketamine clinics are springing up across the country as the total addressable market is estimated to be roughly $16.2 billion.”

“Forward thinking Technology is going to be the next wave of how we receive healthcare,” said Alfred Farrington II, Chief Information Officer of Ehave.

Victor S. Dorodny, MD,ND,PHD,MPH (www.DrDorodny.com), Medical Advisor to Ehave, said, “Ketamine, a widely used anesthetic medication, is now being used to treat depression, suicidality, chronic pain, migraines, OCD and even some PTSD symptoms. For many, this breakthrough treatment represents a powerful opportunity to manage their mental health challenges. KetaDash will allow the patients who are prescribed Ketamine to receive required treatments in the safety and comfort of their homes.”

“Our continued dedication and commitment to mental health has expanded into both telehealth and psychedelics over the past year. As 2020 draws to a close, healthcare providers will need to retool their telehealth efforts in order to prepare for the growing mental health crisis,” said Ben Kaplan, CEO of Ehave, Inc. Mr. Kaplan continued, “KetaDASH will not only provide potentially lifesaving Ketamine infusion therapy for the treatment of psychiatric disorders, such as major depressive disorder, bipolar disorder, and post-traumatic stress disorder, it also provides Ehave the opportunity to build a revenue producing platform.”

Additional Ehave Inc. Information

We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.

The company diligently posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.

Please follow Ehave on Twitter @Ehaveinc1

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. For more information visit: www.ehave.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

For Investor Relations, please contact:

Gabe Rodriguez

Phone: (623) 261-9046

Email: [email protected] 

SAN CARLOS, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA) (BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 2,038,836 shares of its common stock at a purchase price of $5.15 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 18, 2020, subject to the satisfaction of customary closing conditions.

A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333- 249426) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected]. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BioCardia®

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company’s biotherapeutic platforms in clinical development. The Company’s products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit www.BioCardia.com.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the timing and completion of the proposed offering and other statement that are predictive in nature.  These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms.  These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any results, performance or achievements expressed or implied by the forward-looking statements. Such factors include the risk factors set forth in the Company’s filings with the SEC, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2019, its periodic reports on Form 10-Q, and its Current Reports on Form 8-K filed in 2020, as well as the risks identified in the shelf registration statement and the prospectus supplement relating to the offering. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. BioCardia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contact:

Michelle McAdam, Chronic Communications, Inc.
Email: [email protected]
Phone: 310-902-1274

Investor Contact:

David McClung, Chief Financial Officer
Email: [email protected]
Phone: 650-226-0120